E. Davis, “Efficacy of Targeted mRNA Therapeutics in Refractory Autoimmune Disorders: A Phase II Clinical Trial”, Med. Insights, vol. 2, no. 4, pp. 36–47, Nov. 2025, doi: 10.70088/ba518d61.